1. Patients must have biopsy proven metastatic NSCLC (Stage IV).
2. Patients receiving first-line Osimertinib for EGFR mutant-positive for 3 months and achieved stable disease or partial response.
3. Age 18 to 75 years old.
4. Patients must have measurable disease at baseline.
5. The amount of metastatic focus \<5.
6. ECOG score 0-2 7 Adequate normal organ and marrow function for TKI treatment and radiotherapy.
8\. Patients must has sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R) 9. Patients must provide written informed consent to participate in the study.
You may not be if
1. Patients who previously received radiotherapy to the primary site.
2. Patient can't tolerate radiotherapy or targeted therapy;
3. Pregnant or nursing women
Clareo Health | SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC
